Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Testicular Cancer |
Dose: Intravenous – 50-100 mg/m²/day Frequency: once daily on days 1 through 5 Duration: Repeat every 3-4 weeks |
|
Indication: Testicular Cancer |
Dose: Intravenous – 100 mg/m²/day Frequency: once daily on days 1, 3, and 5 Duration: Repeat every 3-4 weeks |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hodgkin's lymphoma Age: Child |
Dose: Intravenous infusion – 75 to 150 mg/m2/day Frequency: once daily Duration: For 2 to 5 days |
|
Indication: non-Hodgkin's lymphoma Age: Child |
Dose: Intravenous infusion – 75 to 150 mg/m2/day Frequency: once daily Duration: For 2 to 5 days |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment with Creatinine Clearance greater than 50 mL/min |
Dose: Not specified Note: Dose adjustment not necessary |
|
Condition: Renal Impairment with Creatinine Clearance 15-50 mL/min |
Dose: Not specified Note: 75% of regular dose |
Administration
- Must be administered by healthcare professionals
- Follow strict medical supervision
Side Effect
- Leukopenia (60-91%)
- Nausea and Vomiting (30-40%)
- Thrombocytopenia (28-41%)
- Alopecia (20-90%)
- Anorexia (13%)
- Diarrhea (13%)
- Leukopenia (60-91%)
- Anemia (≤33%)
- Pancytopenia (7%)
- Stomatitis (6%)
- Hepatic toxicity (3%)
- Type 1 hypersensitivity (2%)
- Orthostatic hypotension (1-2%)
- Peripheral neuropathy (1-2%)
- Malaise
- Shivering
- Asthenia
- Fever
- Mucous membrane inflammation
- Hyperuricemia
- Local soft tissue toxicity has been reported following extravasation
- see section on IV information for extravasation management
- Severe myelosuppression
- characterised by leucopaenia and thrombocytopaenia
- Cardiotoxicity
- Anaphylaxis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Other cytotoxic drugs
|
Synergism
|
|
Drugs that inhibit phosphatase activity
|
Caution when administered together
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.